Can Discharge Via an Intermediate Care Unit Prevent Aggravation of Disease and Loss of Functionality, Without Increasing the Level of Cost? A Controlled Observational Study
Intermediate care unit
+ Local health care 1
+ Local health care 2
Prevention Study
Summary
Study start date: February 1, 2010
Actual date on which the first participant was enrolled.The main goal is to investigate the following topics: Can discharge via the Intermediate Care Unit in Stjørdal, compared to direct discharge to Verdal Municipality, be equally effective in preventing aggravation of disease and loss of function for patients over 60 years that have been hospitalized in Levanger hospital? Are the cost by discharge to the Intermediate Care Unit in Stjørdal, when the hospital is not located in the same Municipality, comparable to the cost by direct discharge to the Municipality of Verdal, for patients over 60 years that have been hospitalized in Levanger hospital? Which issues are considered important by patients and health personnel during discharge, arrival and follow up in the Municipality, to ensure an optimal interaction between the involved units.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.328 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Prevention Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 60 to 99 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Criteria
Inclusion Criteria: Patients 60 years old or older from Stjørdal- or Verdal municipality, given consent, admitted from their home, diagnostics completed and necessary treatment started the patient need not less than 3-4 days institutionalization for treatment/rehabilitation/care Exclusion Criteria: Patients with severe dementia Patients with severe disease who cannot give consent Patients with severe disease with short life expectancy (including severe cancer)
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.3 intervention groups are designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalGroup II
Active ComparatorGroup III
Active ComparatorStudy Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 4 locations
Distriksmedisinsk Senter
Stjørdal, NorwayStjørdal Kommune
Stjørdal, NorwayVerdal kommune
Verdal, Norway